市場調查報告書
商品編碼
1210922
霍亂疫苗全球市場規模和預測:按疫苗類型、副產品(Vaxchora、Dukoral、Shanchol、其他產品)、區域分析,2022-2029 年Global Cholera Vaccines Market Size study & Forecast, by Vaccine Type (Whole cell V. cholerae O1 with Recombinant B-subunit, and Killed Oral O1, and O139), by Product (Vaxchora, Dukoral, Shanchol and Other Products) and Regional Analysis, 2022-2029 |
2021 年全球霍亂疫苗市場價值約為 8650 萬美元,預計在 2022-2029 年預測期內將以超過 8.2% 的健康增長率增長。
引起霍亂的霍亂弧菌通過攝入受污染的食物和水傳播。 受感染的個體會出現急性水樣腹瀉,最終導致脫水。 如果不及時治療,這種情況會導致脫水甚至死亡。 口服免疫療法已被證明是避免霍亂流行最有效的預防措施。 市場增長是由霍亂高發病率和霍亂控制工作數量增加等關鍵因素推動的。
由於多種因素,包括公共和私營部門活動增加、霍亂流行率上升以及全球對該病的認識提高,霍亂疫苗市場正在增長。 據世界衛生組織統計,2020年所有國家報告了1.3至140萬例霍亂病例,其中非洲17例,亞洲12例,歐洲4例,美洲4例。。 80% 的病例發生在海地、剛果民主共和國、越南、也門、秘魯、索馬裡和坦桑尼亞。 然而,疫苗的副作用阻礙了整個 2022-2029 年預測期內的市場增長。
全球霍亂疫苗市場研究考慮的主要區域包括亞太地區、北美、歐洲、拉丁美洲和世界其他地區。 由於發病率高、意識增強和有效預防解決方案的可用性,亞太地區有記錄以來成為最大的地區。 然而,由於前往霍亂疫情國家的旅行增加以及疫苗接種需求增加,預計北美將成為增長最快的地區。
本研究的目的是闡明近年來各個細分市場和國家/地區的市場規模,並預測未來幾年的市場規模。 本報告旨在捕捉被調查國家行業的定性和定量方面的情況。
它還提供了關鍵方面的詳細信息,例如決定市場未來增長的驅動因素和挑戰。 此外,它還包含供利益相關者投資的微觀市場潛在機會,以及對主要參與者的競爭格局和產品供應的深入分析。
Global Cholera Vaccines Market is valued at approximately USD 86.5 million in 2021 and is anticipated to grow with a healthy growth rate of more than 8.2% over the forecast period 2022-2029. Vibrio cholera, which causes cholera, is spread by the intake of contaminated food or water. The infected people experience acute watery diarrhea, which eventually results in dehydration. If this condition is left untreated, the water loss might result in death. In order to avoid cholera epidemics, oral immunization has been found to be the most effective prophylactic measure. The market growth is driven by key players such as high incidence of cholera and rise in the number of initiatives to control cholera
The market for cholera vaccines is expanding as a result of several causes, including rising public and private sector activities, rising cholera prevalence, and increased global awareness of the disease. According to the World Health Organization, there were between 1.3 to 1.4 million cases of cholera reported in 2020 throughout all nations, including 17 in Africa, 12 in Asia, 4 in Europe, and 4 in the Americas. Eighty percent of all cases were in Haiti, the Demographic Republic of the Congo, Vietnam, Yemen, Peru, Somalia, and Tanzania. However, adverse effects of vaccines stifle market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Cholera Vaccines Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia Pacific is recorded to be the largest region owing to high incidence rate, growing awareness, and availability of efficient preventive solutions. However, North America is expected to be the fastest growing region due to number of people traveling to countries with sudden outbreaks of cholera is increasing and demand for immunization is growing.
Major market players included in this report are:
Mitsubishi Tanabe Pharma Corporation
Takeda Pharmaceutical Co., Ltd.
AstraZeneca
GlaxoSmithKline plc (GSK)
Shantha Biotechnics Private Limited
Valneva SE
Astellas Pharma, Inc.
Emergent BioSolutions, Inc.
Pfizer, Inc.
Merck & Co., Inc.
Recent Developments in the Market:
Global Cholera Vaccines Market Report Scope:
Historical Data: 2019-2020-2021
Base Year for Estimation: 2021
Forecast period: 2022-2029
Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered: Vaccine type, Product, Region
Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product:
Vaxchora
Dukoral
Shanchol
Other Products
By Vaccine Type:
Whole cell V. cholerae O1 with Recombinant B-subunit
Killed Oral O1 and O139
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
List of tables and figures and dummy in nature, final lists may vary in the final deliverable